📰 Evaluate Efficacy News
Page 8 - Evaluate Efficacy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Evaluate Efficacy. Real-time updates on events, politics, business and more.
October 29, 2021
The nationwide double-blind study expected to enroll nearly 15,000 participants from across the United States.
October 28, 2021
The nationwide double-blind study expected to enroll nearly 15,000 participants from across the United States.
October 8, 2021
/CNW/ - Apotex Corp. has donated a total of 25,000 fluvoxamine tablets and placebo tablets to the Duke Clinical Research Institute for the ACTIV-6 clinical...
October 7, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial...
October 7, 2021
/PRNewswire/ - Apotex Corp. has donated a total of 25,000 fluvoxamine tablets and placebo tablets to the Duke Clinical Research Institute for the ACTIV-6...
October 7, 2021
ABBVie today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis showing upadacitinib met the primary endpoint of Assessment in SpondyloArthritis International Society 40 response and the majority of ranked secondary endpoints at week 14. 1 Significantly more upadacitinib-treated patients achieved ASAS40 ...
October 7, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active...
October 3, 2021
NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab in Crohns disease, upadacitinib in ulcerative colitis and... | October 3, 2021
October 2, 2021
AbbVie today announced new data on the investigational use of risankizumab in Crohn's disease, upadacitinib in ulcerative colitis and HUMIRA ® in inflammatory bowel disease will be presented as live presentations and e-Posters at the United European Gastroenterology Week Virtual 2021, to be held October 3-5 . AbbVie is presenting a total of 13 abstracts, across a broad range of studies in IBD, including two ...
October 2, 2021
/PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohns disease, upadacitinib (RINVOQ®) in ulcerative...